Somite AI Raises $47 Million Led by Khosla Ventures for AI-Driven DeltaStem Platform and Capsule Technology

Traditional cell therapies are expensive, slow to develop, and difficult to scale. @SomiteAI is building foundation models that systematically solve these challenges, with the potential to not only develop their own pipeline, but reshape the entire field of human cell therapy.

We need more data for ai x science. @conviction is backing novel data generation ideas (at a scale that supports training big models) Somite’s “capsules” (via Allon Klein, prof systems bio at Harvard) is one such innovation — 1,000x’ing stem cell differentiation data

We're excited to announce @FusionFundVC 's investment in @SomiteAi 's oversubscribed $47M Series A round alongside @khoslaventures . We look forward to working with CEO @MichaBreakstone as they unlock the healing potential of stem cell therapy. Read more:

“AI models make it easier to explore biological design space, synthetic biology makes it possible to physically implement novel hypotheses, and lab automation is tightening the loop from software to physical feedback.” @matthewjmandel Biology has become programmable and we’re

Somite is building the blueprints to create any cell type for any person. We call it DeltaStem, our foundation model for the human cell. Our proprietary capsule technology allows us to generate cell signaling data 1,000x faster and more efficiently than current methods,